Ursodeoxycholic Acid in Patients With Chronic Heart Failure: A Double-Blind, Randomized, Placebo-Controlled, Crossover Trial

Stephan von Haehling, Joerg C. Schefold, Ewa A. Jankowska, Jochen Springer, Ali Vazir, Paul R. Kalra, Anja Sandek, Günter Fauler, Tatjana Stojakovic, Michael Trauner, Piotr Ponikowski, Hans-Dieter Volk, Wolfram Doehner, Andrew J. Coats, Philip A. Poole-Wilson, Stefan D. Anker

Research output: Contribution to journalArticlepeer-review

58 Citations (Scopus)


Objectives: This study sought to assess the effects of ursodeoxycholic acid (UDCA) on endothelial function and inflammatory markers in patients with chronic heart failure (CHF).
Background: Endothelial dysfunction is commonly observed in patients with CHF, and it contributes to the limitation in exercise capacity that accompanies this condition. Bacterial lipopolysaccharide may trigger proinflammatory cytokine release and promote further endothelial dysfunction. UDCA, a bile acid used in the treatment of cholestatic liver disease, has anti-inflammatory and cytoprotective properties and may contribute to the formation of mixed micelles around lipopolysaccharide. These properties may help to improve peripheral blood flow in patients with CHF.MethodsWe performed a prospective, single-center, double-blind, randomized, placebo-controlled crossover study of UDCA in 17 clinically stable male patients with CHF (New York Heart Association functional class II/III, left ventricular ejection fraction
Original languageEnglish
Pages (from-to)585-592
Number of pages8
JournalJournal of the American College of Cardiology
Issue number6
Publication statusPublished - 2012

Cite this